Side-by-side comparison of AI visibility scores, market position, and capabilities
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
2024 Revenue: KRW 175.2T (+7.7% YoY) | Operating Profit: KRW 14.2T (-5.9%) | Vehicle Sales: 4.14M units (-1.8%) | Q4 2024: Revenue KRW 46.62T (+11.9%), Op Profit KRW 2.82T (-17.2%) | Electrified Vehicles: 757k units (+8.9%, 21.8% of sales) | US Market: 988k units (+9%) | 2025 guidance: 3-4% revenue growth, 7-8% op margin
Hyundai Motor Company was founded in 1967 in Seoul, South Korea, by Chung Ju-yung and has grown into one of the world's largest automotive manufacturers, ranking third globally by vehicle sales. From its origins as a budget-focused automaker producing affordable, practical vehicles for emerging markets, Hyundai has transformed over the past two decades into a technology-forward brand competing directly with European and Japanese premium manufacturers. Its mission centers on delivering smart mobility solutions for a sustainable future.\n\nHyundai's product lineup spans mass-market sedans, SUVs, and commercial vehicles, alongside its premium Genesis brand and the Ioniq dedicated EV lineup. The Ioniq 5, Ioniq 6, and Ioniq 7 have emerged as critically acclaimed electric vehicles, with the Ioniq 5 winning the World Car of the Year award. Hyundai is also investing heavily in hydrogen fuel cell technology, autonomous driving, and robotics through subsidiaries including Boston Dynamics. Its vehicles are sold in over 200 countries through a network of more than 6,000 dealerships.\n\nHyundai reported revenue of KRW 175.2 trillion in 2024, a 7.7% year-over-year increase, with Q4 2024 revenue of KRW 46.62T (+11.9%). The company sold 4.14M vehicles globally in 2024. With major EV manufacturing investments underway in the United States (Metaplant America in Georgia), Hyundai is positioning itself to be a top-three EV manufacturer globally by 2030, backed by robust R&D spending and a vertically integrated battery and platform strategy.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.